Clinical trial · no report yet · Phase 3
NCT06012435
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- NCT06012435 ↗
- Active not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin; docetaxel
- Arms
- Experimental Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 762
- Primary outcomes
- Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Feb 21, 2024
- Primary completion
- May 18, 2026
- Results posted
- No
- Registry record
- NCT06012435 · updated Jul 23, 2026